0107



OIPE

RAW SEQUENCE LISTING DATE: 01/17/2002 PATENT APPLICATION: US/09/904,117 TIME: 17:44:39

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\I904117.raw

```
1 <110> APPLICANT: MUIR, TOM W.
              COLE, PHILIP A
      2
      3
              FRIEDMAN, JEFFREY M.
              SONDHI, DOLAN
              SEVERINOV, KONSTANITINE
      6 <120> TITLE OF INVENTION: METHODS OF LIGATING EXPRESSED PROTEINS
      7 <130> FILE REFERENCE: 600-1-214CIPB
      8 <140> CURRENT APPLICATION NUMBER: 09/904,117
      9 <141> CURRENT FILING DATE: 2001-07-12
     11 <150> PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/191,890
W--> 12 <151> PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-13
     14 <150> PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/093,990
W--> 15 <151> PRIOR FILING DATE: EARLIER FILING DATE: 1998-07-24
     16 <160> NUMBER OF SEQ ID NOS: 11
     17 <170> SOFTWARE: PatentIn Ver. 2.0
     19 <210> SEQ ID NO: 1
     20 <211> LENGTH: 162
     21 <212> TYPE: PRT
     22 <213> ORGANISM: Artificial Sequence
     23 <220> FEATURE:
     24 <223> OTHER INFORMATION: Description of Artificial Sequence: generated by
              ligation of two proteins under certain conditions
     26 <400> SEQUENCE: 1
     27
              Met Leu Phe Val Ala Leu Tyr Asp Phe Val Ala Ser Gly Asp Asn Thr
     28
     29
              Leu Ser Ile Thr Lys Gly Glu Lys Leu Arg Val Leu Gly Tyr Asn His
     30
                                                25
                                                                    30
     31
              Asn Gly Glu Trp Ala Glu Ala Gln Thr Lys Asn Gly Gln Gly Trp Val
     32
                                            40
     33
              Pro Ser Asn Tyr Ile Thr Pro Val Gly Cys Leu Glu Lys His Ser Trp
     34
                                       55
     35
              Tyr His Gly Pro Val Ser Arg Asn Ala Ala Glu Tyr Leu Leu Ser Ser
     36
                                                        75
                                   70
     37
              Gly Ile Asn Gly Ser Phe Leu Val Arg Glu Ser Glu Ser Ser Pro Gly
     38
                               85
                                                    90
     39
              Gln Arg Ser Ile Ser Leu Arg Tyr Glu Gly Arg Val Tyr His Tyr Arg
     40
                                               105
                          100
     41
              Ile Asn Thr Ala Ser Asp Gly Lys Leu Tyr Val Ser Ser Glu Ser Arg
     42
                                           120
     43
              Phe Asn Thr Leu Ala Glu Leu Val His His His Ser Thr Val Ala Asp
     44
                                      135
     45
              Gly Leu Ile Thr Thr Leu His Tyr Pro Ala Pro Lys Arg Gly Ile His
     46
              145
                                  150
                                                       155
```

DATE: 01/17/2002

TIME: 17:44:39

```
Input Set : N:\Crf3\RULE60\09904117.raw
                     Output Set: N:\CRF3\01172002\I904117.raw
     47
              Arg Asp
     49 <210> SEQ ID NO: 2
     50 <211> LENGTH: 12
     51 <212> TYPE: PRT
     52 <213> ORGANISM: Artificial Sequence
     53 <220> FEATURE:
     54 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
              synthesized by solid phase peptide synthesis.
     56 <220> FEATURE:
     57 <221> NAME/KEY: SITE
     58 <222> LOCATION: (11)
     59 <223> OTHER INFORMATION: Xaa(position 11) is aminocaproate.
     60 <220> FEATURE:
     61 <223> OTHER INFORMATION: C-terminal K has a fluorescein moiety off the
     62
              E-NH2 group.
     63 <400> SEQUENCE: 2
W--> 64
              Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys
     65
     67 <210> SEQ ID NO: 3
     68 <211> LENGTH: 12
     69 <212> TYPE: PRT
     70 <213> ORGANISM: Artificial Sequence
     71 <220> FEATURE:
     72 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
     73
              synthesized by solid phase peptide synthesis.
     74 <220> FEATURE:
     75 <221> NAME/KEY: SITE
     76 <222> LOCATION: (11)
     77 <223> OTHER INFORMATION: Xaa(position 11) is aminocaproate.
     78 <400> SEQUENCE: 3
W--> 79
              Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys
     80
                                5
                                                    10
     82 <210> SEQ ID NO: 4
     83 <211> LENGTH: 8
     84 <212> TYPE: PRT
     85 <213> ORGANISM: Artificial Sequence
     86 <220> FEATURE:
     87 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
              synthesized by solid phase peptide synthesis.
     89 <220> FEATURE:
     90 <223> OTHER INFORMATION: K has a fluorescein moiety off the E-NH2 group; C-
     91
              terminus is an amide group.
     92 <400> SEQUENCE: 4
     93
              Cys Gly Arg Gly Arg Lys
     96 <210> SEQ ID NO: 5
     97 <211> LENGTH: 8
     98 <212> TYPE: PRT
     99 <213> ORGANISM: Unknown
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/904,117

RAW SEQUENCE LISTING DATE: 01/17/2002 PATENT APPLICATION: US/09/904,117 TIME: 17:44:39

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\1904117.raw

```
100 <220> FEATURE:
101 <223> OTHER INFORMATION: Description of Unknown Organism: ligand
102 <400> SEQUENCE: 5
          Pro Val Pro Tyr Glu Asn Val Gly
103
104
106 <210> SEQ ID NO: 6
107 <211> LENGTH: 11
108 <212> TYPE: PRT
109 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
112
          synthesized by solid phase peptide synthesis.
113 <220> FEATURE:
114 <223> OTHER INFORMATION: C-terminus is an amide group.
115 <400> SEQUENCE: 6
          Pro Pro Ala Tyr Pro Pro Pro Pro Val Pro Lys
116
117
119 <210> SEQ ID NO: 7
120 <211> LENGTH: 42
121 <212> TYPE: DNA
122 <213> ORGANISM: Artificial Sequence
123 <220> FEATURE:
124 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
          oligonucleotide
125
126 <400> SEQUENCE: 7
          ccggtcatcg aaggtcgttg cctggagaaa cattcctggt at
                                                                              42
127
129 <210> SEQ ID NO: 8
130 <211> LENGTH: 41
131 <212> TYPE: DNA
132 <213> ORGANISM: Artificial Sequence
133 <220> FEATURE:
134 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
          oligonucleotide
136 <400> SEQUENCE: 8
137
          catgatacca ggaatgtttc tccaggcaac gaccttcgat g
                                                                              41
139 <210> SEQ ID NO: 9
140 <211> LENGTH: 5
141 <212> TYPE: PRT
142 <213> ORGANISM: Artificial Sequence
143 <220> FEATURE:
144 <223> OTHER INFORMATION: Description of Artificial Sequence: motif within
          linker region
145
146 <400> SEQUENCE: 9
147
          Ile Glu Gly Arg Cys
148
150 <210> SEQ ID NO: 10
151 <211> LENGTH: 45
152 <212> TYPE: DNA
153 <213> ORGANISM: Artificial Sequence
```

RAW SEQUENCE LISTING DATE: 01/17/2002 PATENT APPLICATION: US/09/904,117 TIME: 17:44:39

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\1904117.raw

154	<220>	FEATURE:	
155	<223>	OTHER INFORMATION: Description of Artificial Sequence: synthetic	
156		oligonucleotide	
157	<400>	SEQUENCE: 10	
158		ggatcccctg gtcatatgct ttttgtggca ctctatgatt ttgtg	45
160	<210>	SEQ ID NO: 11	
161	<211>	LENGTH: 42	
162	<212>	TYPE: DNA	
163	<213>	ORGANISM: Artificial Sequence	
		FEATURE:	
165	<223>	OTHER INFORMATION: Description of Artificial Sequence: synthetic	
166		oligonucleotide	
167	<400>	SEQUENCE: 11	
168		atgtttctcc aggctgttaa cgggggtgat gtagttgctt gg	42

VERIFICATION SUMMARY

DATE: 01/17/2002

PATENT APPLICATION: US/09/904,117

TIME: 17:44:40

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\1904117.raw

L:12 M:256 W: Invalid Numeric Header Field, Wrong Prior FILING DATE:YYYY-MM-DD L:15 M:256 W: Invalid Numeric Header Field, Wrong Prior FILING DATE:YYYY-MM-DD

L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 L:79 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3